Company Profile

StemSynergy Therapeutics Inc
Profile last edited on: 1/14/2019      CAGE: 59DT1      UEI: WVEMHJFUNJ97

Business Identifier: Stem-cell research and small-molecule drugs targeting developmental pathways fundamental to cancer
Year Founded
2007
First Award
2010
Latest Award
2022
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1951 Northwest 7th Avenue Suite 300
Miami, FL 33136
   (305) 753-0217
   capobianco@stemsynergy.com
   www.stemsynergy.com
Location: Single
Congr. District: 24
County: Miami-Dade

Public Profile

StemSynergy Therapeutics Inc. (SSTI) is a biopharmaceutical company that focuses on the discovery and development of small-molecule drugs targeting developmental pathways fundamental to cancer. The goal of the company's cancer program is to develop novel therapeutics to treat cancer by targeting cellular processes that are deregulated in cancer stem cells. Its drugs act in combination with standard-of-care agents that target the bulk of the cancer cells, with the overall aim of eliminating the cancer. SSTI is focused on breakthrough technologies in WNT and Sonic Hedgehog (SHH) signaling. In January 2018 StemSynergy Inc. and Exelixis Inc. joined forces to develop new cancer compounds that target casein kinase 1 alpha (CK1a), a component of the Wnt signaling pathway.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Key People / Management

  Anthony Capobianco -- President

  Thomas Doundoulakis -- Senior Principal Scientist

  Dennis Liang Fei

  Marcy Guerra -- Senior Biological Scientist

  William Russell Guerrant

  Kellye Kirkbride -- Senior Biological Scientist

  Darren Orton -- Director of Medicinal Chemisty